Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an announcement.
Shanghai Henlius Biotech, Inc. has renewed two key procurement agreements with Fosun High Tech for one year, extending their collaboration until the end of 2025. These agreements, covering general procurement and IT-related services, are crucial for the company’s operational efficiency and compliance with listing rules, highlighting the strategic importance of their partnership with a major shareholder.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a joint stock company based in China, operating in the biotechnology industry. The company focuses on developing and manufacturing biopharmaceutical products, with a market emphasis on providing innovative healthcare solutions.
YTD Price Performance: 28.69%
Average Trading Volume: 1,441,157
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.58B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com